Suffolk Capital Management’s Sage Therapeutics SAGE Stock Holding History

Suffolk Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$10.7M	Buy	111,908 +18,908	+20%	+$2.16M	2.06%	12
2018 Q3	$13.1M	Buy	93,000 +17,536	+23%	+$2.71M	1.87%	21
2018 Q2	$11.8M	Buy	75,464 +20,609	+38%	+$3.24M	1.68%	34
2018 Q1	$8.84M	Sell	54,855 -8,321	-13%	-$1.41M	1.25%	39
2017 Q4	$10.4M	Buy	63,176 +47,665	+307%	+$4.62M	1.35%	37
2017 Q3	$966K	Sell	15,511 -4,823	-24%	-$379K	0.13%	103
2017 Q2	$1.62M	Sell	20,334 -3,570	-15%	-$258K	0.21%	80
2017 Q1	$1.7M	Buy	23,904 +4,500	+23%	+$264K	0.23%	61
2016 Q4	$991K	Buy	+19,404	New	+$915K	0.14%	121

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Suffolk Capital Management's SAGE Position: Q4 2018 in Review

Suffolk Capital Management increased its Sage Therapeutics (SAGE) stake by 20% in Q4 2018, buying an estimated $2.16M and bringing the position to 111,908 shares worth $10.7M. The position accounts for 2.06% of the portfolio, ranked #12.

Suffolk Capital Management first reported a position in SAGE in Q4 2016 and has held it in 9 quarters since. The position peaked at $13.1M in Q3 2018. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

Suffolk Capital Management held 111,908 shares of Sage Therapeutics worth $10.7M as of Q4 2018.
Suffolk Capital Management bought 18,908 Sage Therapeutics shares in Q4 2018, an estimated $2.16M.
Sage Therapeutics made up 2.06% of Suffolk Capital Management's portfolio in Q4 2018, its #12 holding.
Suffolk Capital Management first reported a position in Sage Therapeutics in Q4 2016 and has held it in 9 quarters since.
Suffolk Capital Management's Sage Therapeutics position peaked at $13.1M in Q3 2018.
248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Suffolk Capital Management's 13F filing for Q4 2018, filed 23 Jan 2019.